330 related articles for article (PubMed ID: 25869733)
21. Cardiotoxicity and cancer therapy: treatment-related cardiac morbidity in patients presenting with symptoms suggestive of heart or lung disease.
Wieshammer S; Dreyhaupt J; Müller D; Momm F; Jakob A; Freund U
Oncology; 2013; 85(3):137-44. PubMed ID: 23948797
[TBL] [Abstract][Full Text] [Related]
22. Cardiac toxicity of anticancer agents.
Colombo A; Cipolla C; Beggiato M; Cardinale D
Curr Cardiol Rep; 2013 May; 15(5):362. PubMed ID: 23512625
[TBL] [Abstract][Full Text] [Related]
23. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
24. NT-proBNP as early marker of subclinical late cardiotoxicity after doxorubicin therapy and mediastinal irradiation in childhood cancer survivors.
Zidan A; Sherief LM; El-sheikh A; Saleh SH; Shahbah DA; Kamal NM; Sherbiny HS; Ahmad H
Dis Markers; 2015; 2015():513219. PubMed ID: 25960594
[TBL] [Abstract][Full Text] [Related]
25. Cancer Therapy-Related Cardiac Dysfunction: Unresolved Issues.
Marwick TH
Can J Cardiol; 2016 Jul; 32(7):842-6. PubMed ID: 27343742
[TBL] [Abstract][Full Text] [Related]
26. Use of cardiac biomarkers in neonatology.
Vijlbrief DC; Benders MJ; Kemperman H; van Bel F; de Vries WB
Pediatr Res; 2012 Oct; 72(4):337-43. PubMed ID: 22797141
[TBL] [Abstract][Full Text] [Related]
27. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology.
Joolharzadeh P; Rodriguez M; Zaghlol R; Pedersen LN; Jimenez J; Bergom C; Mitchell JD
Curr Cardiol Rep; 2023 Mar; 25(3):133-146. PubMed ID: 36790618
[TBL] [Abstract][Full Text] [Related]
29. The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Podlecka-Piętowska A; Kochanowski J; Zakrzewska-Pniewska B; Opolski G; Kwieciński H; Kamińska AM
Neurol Neurochir Pol; 2014; 48(2):111-5. PubMed ID: 24821636
[TBL] [Abstract][Full Text] [Related]
30. The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
Brown SA; Okwuosa TM; Barac A; Volgman AS
J Am Heart Assoc; 2020 Jan; 9(2):e015327. PubMed ID: 31960742
[No Abstract] [Full Text] [Related]
31. Imaging methods for detection of chemotherapy-associated cardiotoxicity and dysfunction.
Ong DS; Scherrer-Crosbie M; Coelho-Filho O; Francis SA; Neilan TG
Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):487-97. PubMed ID: 24650314
[TBL] [Abstract][Full Text] [Related]
32. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
34. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
35. Role of biomarkers in monitoring antiblastic cardiotoxicity.
Novo G; Cadeddu C; Sucato V; Pagliaro P; Romano S; Tocchetti CG; Zito C; Longobardo L; Nodari S; Penco M
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e27-e34. PubMed ID: 27755240
[TBL] [Abstract][Full Text] [Related]
36. Detection and monitoring of cardiotoxicity-what does modern cardiology offer?
Jurcut R; Wildiers H; Ganame J; D'hooge J; Paridaens R; Voigt JU
Support Care Cancer; 2008 May; 16(5):437-45. PubMed ID: 18197426
[TBL] [Abstract][Full Text] [Related]
37. Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity.
Avila MS; Siqueira SRR; Ferreira SMA; Bocchi EA
Methodist Debakey Cardiovasc J; 2019; 15(4):267-273. PubMed ID: 31988687
[TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.
Che F; Liu Y; Xu C
Int J Toxicol; 2011 Dec; 30(6):681-9. PubMed ID: 21994238
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
[TBL] [Abstract][Full Text] [Related]
40. [Cardiologic evaluation of patients undergoing chemotherapy].
Bordoni B; Urbinati S; Tosoni A; Labanti G; Brandes A
Monaldi Arch Chest Dis; 2014 Jun; 82(2):68-74. PubMed ID: 25845089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
